Want to see AU:DXB full AI Analyst Report?

Dimerix Limited (DXB) Price & Analysis

98 Followers

DXB Stock Chart & Stats

AU$0.40

-AU$0.03(-5.00%)

At close: Jan 09 4:00 PM EST

AU$0.40

-AU$0.03(-5.00%)

Day’s Range― - ―

52-Week RangeAU$0.16 - AU$0.67

Previous CloseN/A

Volume4.60M

Average Volume (3M)1.47M

Market Cap

AU$144.10M

Enterprise ValueAU$75.62M

Total Cash (Recent Filing)AU$38.49M

Total Debt (Recent Filing)AU$33.42K

Price to Earnings (P/E)―

Beta2.72

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding600,396,800

10 Day Avg. Volume1,720,426

30 Day Avg. Volume1,468,144

Financial Highlights & Ratios

PEG Ratio0.65

Price to Book (P/B)24.09

Price to Sales (P/S)256.86

P/FCF Ratio8.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)AU$7.20M

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthSustained high top-line expansion (70.03% year) signals growing commercial traction or successful clinical/partnership milestones. Over 2-6 months this durable revenue momentum can provide expanding operating scale, improve fixed-cost absorption, and support continued R&D investment without immediate dilution.

Very Low LeverageAn extremely low debt load gives the company long-term financial flexibility, reducing interest burden and refinancing risk. This conservative capital structure supports the ability to fund clinical programs through equity or partnerships and withstands revenue variability common in biotech cycles.

Operating Cash ConversionStrong cash conversion (OCF/net income 1.76 and FCF roughly aligned with net income) indicates earnings are translating into cash. This durability in cash generation underpins operational sustainability, aids working capital management, and reduces near-term dependence on external financing for program execution.

Bears Say

Persistent Negative MarginsContinued negative operating and net margins indicate the business has not yet achieved profitable unit economics. Over a medium horizon this undermines internal funding for development, increases reliance on external capital, and raises execution risk if revenue growth slows or costs remain elevated.

Very Negative ROEAn ROE near -100% signals severe inefficiency in generating returns from equity, often due to accumulated losses. Structural capital destruction makes it harder to attract long-term investors and suggests that without a clear path to profitability, equity dilution or costly financing may be necessary to sustain operations.

Sharp Free Cash Flow DeclineA large fall in free cash flow growth over the period indicates weakening cash generation trends despite OCF alignment. This deterioration pressures runway and funding flexibility, increasing the risk that management must pursue dilutive financing or cut discretionary investment in trials and discovery programs.

Dimerix Limited News

Dimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200

Dimerix Limited ( ($AU:DXB) ) just unveiled an update. Dimerix has signed an exclusive licensing agreement granting Everest...

29d ago

DXB

Dimerix Highlights ACTION3 Trial De-Risking and Commercial Potential for DMX-200

Dimerix Limited ( ($AU:DXB) ) just unveiled an announcement. Dimerix Limited has released an updated investor presentation and...

3M ago

DXB

Dimerix Confirms Strong Statistical Power and Refines Strategy for Phase 3 FSGS Trial

The latest update is out from Dimerix Limited ( ($AU:DXB) ). Dimerix has confirmed that its Phase 3...

3M ago

DXB

Dimerix to Court Singapore Investors With Update on Phase 3 Kidney Drug

Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited has announced an updated venue and details...

3M ago

DXB

Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix has completed enrolment and first dosing of the...

4M ago

DXB

Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program

The latest announcement is out from Dimerix Limited ( ($AU:DXB) ). Dimerix Limited has invited existing and potential...

4M ago

DXB

Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference

Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited will present an update on its Phase...

5M ago

DXB

Dimerix Revenue Surges but Loss Deepens and Asset Base Thins

Dimerix Limited ( ($AU:DXB) ) has provided an update. Biotechnology developer Dimerix Limited reported a sharp increase in...

5M ago

DXB

Dimerix to Showcase Phase 3 FSGS Program and Growth Strategy at Euroz Hartleys Healthcare Forum

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix Limited announced that CEO and Managing Director Dr...

5M ago

DXB

Dimerix Hits Phase 3 Recruitment Target for Lead Kidney Drug as FDA Backs Approval Pathway

Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix reported strong operational progress in the December 2025...

6M ago

DXB

DXB FAQ

What was Dimerix Limited’s price range in the past 12 months?

Dimerix Limited lowest share price was AU$0.16 and its highest was AU$0.67 in the past 12 months.

What is Dimerix Limited’s market cap?

Dimerix Limited’s market cap is AU$144.10M.

When is Dimerix Limited’s upcoming earnings report date?

Dimerix Limited’s upcoming earnings report date is Sep 02, 2026 which is in 49 days.

How were Dimerix Limited’s earnings last quarter?

Dimerix Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.027.

Is Dimerix Limited overvalued?

According to Wall Street analysts Dimerix Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Dimerix Limited pay dividends?

Dimerix Limited does not currently pay dividends.

What is Dimerix Limited’s EPS estimate?

Dimerix Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Dimerix Limited have?

Dimerix Limited has 600,396,800 shares outstanding.

What happened to Dimerix Limited’s price movement after its last earnings report?

Dimerix Limited reported an EPS of -AU$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.409%.

Which hedge fund is a major shareholder of Dimerix Limited?

Currently, no hedge funds are holding shares in AU:DXB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dimerix Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-278.87%

Trailing 12-Months

Asset Growth

194.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dimerix Limited

Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.